Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 9Lung Neoplasms 9Oropharyngeal Neoplasms 7Mouth Neoplasms 6Laryngeal Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Stomach Neoplasms 4Hypopharyngeal Neoplasms 4Breast Neoplasms 4Adenocarcinoma of Lung 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Paranasal Sinus Neoplasms 2Ovarian Neoplasms 2Medulloblastoma 2Lymphoid Interstitial Pneumonia 2Liver Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Anus Neoplasms 2Urethral Neoplasms 1

Interventions

Etoposide 2olaparib 1ceralasertib 1apatinib 1anlotinib 1Platinum 1Paclitaxel 1Immune Checkpoint Inhibitors 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × SCLC × Platinum × Clear all
NCT05844150 2025-03-12

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Biotheus Inc.

Phase 2 Active not recruiting
50 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡